Drug Information

Drug (ID: DG00354) and It's Reported Resistant Information

• Name: Iridium
• Synonyms: 7439-88-5; Ir; Iridium; Iridium black; iridium atom; Iridium wire; iridium ion (4+); Iridium, powder; MFCD00011062; Iridium metallicum; Iridium, elemental; Iridium, ion(Ir4 ); hydrido-iridium; Iridium powder; Iridium sponge; Iridium foil; Iridium-Mohr; iridium dihydride; Iridium Nanorods; Iridium compounds; HSDB 7067; Iridium Nanowires; iridium pentahydride; Iridium single crystal disc, 10mm (0.39in) dia, 1-2mm (0.04-0.08in) thick, (110) orientation, +/-0.5 degrees; EINECS 231-095-9; iridium(4+); iridium(iv) hydride; Iridium (IV) ion; Iridium Nanoparticles; UNII-44448S9773; Ir/C; Iridium powder, -60 mesh; Iridium powder, -325 mesh; Iridium sponge, -100 mesh; DTXSID0064674; CHEBI:49666; HSDB 7066; Ir(4+); 7282AH; Iridium, powder, puriss., 99.9%; Iridium powder, -22 mesh, Premion ; AKOS015833373; Iridium wire, 0.5mm (0.02in) dia; Iridium wire, 1.0mm (0.04in) dia; Iridium foil, 0.5mm (0.02in) thick; Iridium foil, 1.0mm (0.04in) thick; Iridium wire, 0.25mm (0.01in) dia; Q877; Iridium foil, 0.05mm (0.002in) thick; Iridium shot, 6-7mm (0.24-0.28in); Iridium wire, 0.075mm (0.003in) dia; Iridium wire, 0.125mm (0.005in) dia; CS-0082565; FT-0627287; Iridium, powder, 99.9% trace metals basis; Iridium foil, 0.25mm (0.01in) thick, hard; Iridium foil, 0.127mm (0.005in) thick, hard; Iridium pellet, approximately 1.3cm (0.5in) dia; Lanthanum Nickel Oxide (LaNiO3) Sputtering Targets; Q27461515; 44448S9773; I000000010; Iridium, sponge, -20 mesh, 99.9% trace metals basis; Iridium, AAS standard solution, Specpure , Ir 1000 g/ml; Iridium, rod, 100mm, diameter 2.0mm, as drawn, 99.9%; Iridium, rod, 100mm, diameter 3.0mm, as drawn, 99.9%; Iridium, rod, 25mm, diameter 2.0mm, as drawn, 99.9%; Iridium, rod, 25mm, diameter 3.0mm, as drawn, 99.9%; Iridium, rod, 50mm, diameter 2.0mm, as drawn, 99.9%; Iridium, rod, 50mm, diameter 3.0mm, as drawn, 99.9%; Iridium, wire, diam. 0.15 mm, 99.9% trace metals basis; Iridium, wire, diam. 0.5 mm, 99.9% trace metals basis; Iridium slug, 6.0mm (0.24in) dia x 6.0mm (0.24in) length; Iridium, black, powder, -200 mesh, >=99% trace metals basis; Iridium, foil, thickness 0.07 mm, 99.5% trace metals basis; Iridium, foil, thickness 0.1 mm, 99.5% trace metals basis; Iridium, foil, thickness 0.25 mm, 99.9% trace metals basis; Iridium, plasma standard solution, Specpure , Ir 10,000 g/ml; Iridium, plasma standard solution, Specpure , Ir 1000 g/ml; Iridium, rod, 4.0 mm diameter, length 25 mm, purity 99.9%; Iridium, rod, 4.0 mm diameter, length 50 mm, purity 99.9%; Iridium, wire reel, 0.1m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.2mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.8mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 1.0mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 2.0mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.2mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.8mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 1.0mm, as drawn, 99.9%; Iridium, wire reel, 0.3m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 0.4m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.2mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.5mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 1m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.15mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.177mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.25mm, as drawn, 99.9%; Iridium, wire reel, 1m, diameter 0.2mm, as drawn, 99.9%; Iridium, wire reel, 2m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 2m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 2m, diameter 0.15mm, as drawn, 99.9%; Iridium slug, 6.0mm (0.24in) dia x 12.0mm (0.48in) length; Iridium, foil, 25x25mm, thickness 0.125mm, as rolled, 99.9%; Iridium, foil, 25x25mm, thickness 0.15mm, as rolled, 99.9%; Iridium, foil, 25x25mm, thickness 0.25mm, as rolled, 99.9%; Iridium, foil, thickness 0.1 mm, size 25 x 25 mm, purity 99.9%; Iridium, wire reel, 0.025m, diameter 2.0mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 0.1mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 0.8mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 1.0mm, as drawn, 99.9%; Iridium, wire reel, 0.05m, diameter 2.0mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 0.1m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.15mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.177mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.25mm, as drawn, 99.9%; Iridium, wire reel, 0.1m, diameter 0.38mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 0.2m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.15mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.177mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.25mm, as drawn, 99.9%; Iridium, wire reel, 0.2m, diameter 0.38mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.075mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.125mm, as drawn, 99.5%; Iridium, wire reel, 0.5m, diameter 0.125mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.15mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.177mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.25mm, as drawn, 99.9%; Iridium, wire reel, 0.5m, diameter 0.38mm, as drawn, 99.9%; Iridium, wire, 0.25 mm diameter, size 100 mm, purity 99.9%; Iridium, wire, 0.25 mm diameter, size 1000 mm, purity 99.9%; Iridium, wire, 0.25 mm diameter, size 200 mm, purity 99.9%; Iridium, wire, 0.25 mm diameter, size 500 mm, purity 99.9%; Iridium, wire, straight, 100mm, diameter 0.5mm, as drawn, 99.9%; Iridium, wire, straight, 100mm, diameter 0.6mm, as drawn, 99.9%; Iridium, wire, straight, 100mm, diameter 0.7mm, as drawn, 99.9%; Iridium, wire, straight, 100mm, diameter 0.8mm, as drawn, 99.9%; Iridium, wire, straight, 100mm, diameter 1.0mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 0.5mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 0.6mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 0.7mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 0.8mm, as drawn, 99.9%; Iridium, wire, straight, 200mm, diameter 1.0mm, as drawn, 99.9%; Iridium, wire, straight, 500mm, diameter 0.5mm, as drawn, 99.9%; Iridium, wire, straight, 50mm, diameter 0.6mm, as drawn, 99.9%; Iridium, wire, straight, 50mm, diameter 0.7mm, as drawn, 99.9%; Iridium, wire, straight, 50mm, diameter 0.8mm, as drawn, 99.9%; Iridium, wire, straight, 50mm, diameter 1.0mm, as drawn, 99.9%; Iridium, 0.5% on activated carbon powder, reduced, nominally 50% water wet; Iridium, foil, thickness 0.03 mm, size 25 x 25 mm, purity 99.9%; Iridium, powder, 50 max. part. size (micron), weight 5 g, purity 99.9%; Iridium, powder, max. particle size 50 micron, weight 1 g, purity 99.9%; Iridium, powder, max. particle size 50 micron, weight 2 g, purity 99.9%; Iridium, evaporation slug, diam. x L 0.6 cm x 1.2 cm, 99.9% trace metals basis; Iridium, foil, 0.025m coil, thickness 0.05mm, coil width .5mm, as rolled, 99.9%; Iridium, foil, 0.05m coil, thickness 0.05mm, coil width .5mm, as rolled, 99.9%; Iridium, foil, 0.18m coil, thickness 0.05mm, coil width .5mm, as rolled, 99.9%; Iridium, foil, 0.1m coil, thickness 0.05mm, coil width .5mm, as rolled, 99.9%; Iridium, foil, light tested, 25x25mm, thickness 0.025mm, as rolled, 99.9%; Iridium, foil, light tested, 25x25mm, thickness 0.05mm, as rolled, 99.9%; Iridium, foil, light tested, 50x50mm, thickness 0.025mm, as rolled, 99.9%; Iridium, foil, light tested, 50x50mm, thickness 0.05mm, as rolled, 99.9%; Iridium, powder, 850 max. part. size (micron), high purity 99.995%, weight 1 g; Iridium, powder, 850 max. part. size (micron), weight 2 g, high purity 99.995%; Iridium single crystal disc, 10mm (0.39in) dia, 1-2mm (0.04-0.08in) thick, (100) orientation, +/-0.5 degrees; Iridium single crystal disc, 10mm (0.39in) dia, 1-2mm (0.04-0.08in) thick, (111) orientation, +/-0.5 degrees; Iridium, microfoil, disks, 10mm, thinness 0.1mum, specific density 224mug/cm2, permanent mylar 3.5mum support, 99.9%; Iridium, microfoil, disks, 25mm, thinness 0.1mum, specific density 224mug/cm2, permanent mylar 3.5mum support, 99.9%
• Formula: Ir
• IsoSMILES: [Ir]
• InChI: 1S/Ir
• InChIKey: GKOZUEZYRPOHIO-UHFFFAOYSA-N
• PubChem CID: 23924

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Osteosarcoma [ICD-11: 2B51]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: hsa-mir-124 [1]

• Molecule Alteration: Expression; Up-regulation
• Sensitive Disease: Osteosarcoma [ICD-11: 2B51.0]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• Cell Pathway Regulation: Cell proliferation; Inhibition; hsa05200
• Cell Pathway Regulation: PI3K/AKT signaling pathway; Inhibition; hsa04151
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• In Vitro Model: T47D cells; Breast; Homo sapiens (Human); CVCL_0553
• In Vitro Model: ZR75-1 cells; Breast; Homo sapiens (Human); CVCL_0588
• In Vitro Model: HCC1937 cells; Breast; Homo sapiens (Human); CVCL_0290
• Experiment for Molecule Alteration: RT-PCR
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance.

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: ATM interactor (ATMIN) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Osteosarcoma [ICD-11: 2B51.0]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• Cell Pathway Regulation: Cell proliferation; Inhibition; hsa05200
• Cell Pathway Regulation: PI3K/AKT signaling pathway; Inhibition; hsa04151
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• In Vitro Model: T47D cells; Breast; Homo sapiens (Human); CVCL_0553
• In Vitro Model: ZR75-1 cells; Breast; Homo sapiens (Human); CVCL_0588
• In Vitro Model: HCC1937 cells; Breast; Homo sapiens (Human); CVCL_0290
• In Vivo Model: Nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance.

Key Molecule: Poly[ADP-ribose] synthase 1 (PARP1) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Osteosarcoma [ICD-11: 2B51.0]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• Cell Pathway Regulation: Cell proliferation; Inhibition; hsa05200
• Cell Pathway Regulation: PI3K/AKT signaling pathway; Inhibition; hsa04151
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• In Vitro Model: T47D cells; Breast; Homo sapiens (Human); CVCL_0553
• In Vitro Model: ZR75-1 cells; Breast; Homo sapiens (Human); CVCL_0588
• In Vitro Model: HCC1937 cells; Breast; Homo sapiens (Human); CVCL_0290
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance.

Breast cancer [ICD-11: 2C60]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: hsa-mir-124 [1]

• Molecule Alteration: Expression; Up-regulation
• Sensitive Disease: Breast cancer [ICD-11: 2C60.3]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• Cell Pathway Regulation: Cell proliferation; Inhibition; hsa05200
• Cell Pathway Regulation: PI3K/AKT signaling pathway; Inhibition; hsa04151
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• In Vitro Model: T47D cells; Breast; Homo sapiens (Human); CVCL_0553
• In Vitro Model: ZR75-1 cells; Breast; Homo sapiens (Human); CVCL_0588
• In Vitro Model: HCC1937 cells; Breast; Homo sapiens (Human); CVCL_0290
• Experiment for Molecule Alteration: RT-PCR
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance.

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: ATM interactor (ATMIN) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Breast cancer [ICD-11: 2C60.3]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• Cell Pathway Regulation: Cell proliferation; Inhibition; hsa05200
• Cell Pathway Regulation: PI3K/AKT signaling pathway; Inhibition; hsa04151
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• In Vitro Model: T47D cells; Breast; Homo sapiens (Human); CVCL_0553
• In Vitro Model: ZR75-1 cells; Breast; Homo sapiens (Human); CVCL_0588
• In Vitro Model: HCC1937 cells; Breast; Homo sapiens (Human); CVCL_0290
• In Vivo Model: Nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance.

Key Molecule: Poly[ADP-ribose] synthase 1 (PARP1) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Breast cancer [ICD-11: 2C60.3]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• Cell Pathway Regulation: Cell proliferation; Inhibition; hsa05200
• Cell Pathway Regulation: PI3K/AKT signaling pathway; Inhibition; hsa04151
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• In Vitro Model: T47D cells; Breast; Homo sapiens (Human); CVCL_0553
• In Vitro Model: ZR75-1 cells; Breast; Homo sapiens (Human); CVCL_0588
• In Vitro Model: HCC1937 cells; Breast; Homo sapiens (Human); CVCL_0290
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance.

References

• Ref 1: The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One. 2015 Jun 26;10(6):e0128472. doi: 10.1371/journal.pone.0128472. eCollection 2015.